Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Ivuxolimab

Catalog No. T78275 Copy Product Info
Purity: 95%
🥰Excellent
Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Ivuxolimab

Copy Product Info
🥰Excellent
Catalog No. T78275

Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Ivuxolimab
Cas No. 2128729-41-7
TargetMol | Customer service
Customer service consultation
Pack SizePriceUSA StockGlobal StockQuantity
1 mg$213-In Stock
5 mg$553-In Stock
10 mg$868-In Stock
25 mg$1,280-In Stock
50 mg$1,730-In Stock
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:96.0% (SDS-PAGE); 96.7% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.
In vivo
Methods: Ivuxolimab (10 mg/kg, intravenous injection, twice a week for 3 weeks) was used to treat mice bearing a CT26 tumor model, and its effect on tumors in mice was observed. Results: Ivuxolimab significantly inhibited tumor growth in the CT26 tumor model without causing significant weight loss. [1]
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetTNFRSF4/OX40/CD134
Chemical Properties
Molecular Weight144.18 kDa
Cas No.2128729-41-7
Antibody Information
IsotypeHuman IgG2 kappa
Recommended Isotype Control
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Ivuxolimab | purchase Ivuxolimab | Ivuxolimab cost | order Ivuxolimab | Ivuxolimab in vivo | Ivuxolimab molecular weight